2Pi

2Pi Therapeutics was a biotechnology company focused on the discovery and development of next-generation proteasome inhibitors for the treatment of cancer. The company's technology was based on research from the University of California, Berkeley, and the University of Utah, specifically focusing on irreversible inhibitors of the 20S proteasome. These novel compounds were designed to offer improved potency and selectivity compared to first-generation inhibitors like bortezomib. In 2011, the company was acquired by Onyx Pharmaceuticals to bolster their oncology pipeline and complement their lead proteasome inhibitor, Kyprolis (carfilzomib).